ROCKVILLE, Md.--(BUSINESS WIRE)--Celera Group (NYSE:CRA), an Applera Corporation business, today reported a net loss of $0.5 million, or $0.01 per share, for the second quarter of fiscal 2007, compared to a net loss of $17.3 million, or $0.23 per share, for the second quarter of fiscal 2006. Included in the results for the second quarter of fiscal 2007 were items that increased income before taxes by approximately $2.4 million. Results for the second quarter of fiscal 2007 included a pre-tax gain of $2.5 million from the sale of a small molecule drug discovery and development program and a pre-tax gain of $2.4 million from a legal settlement. These gains were partially offset by a pre-tax charge of $2.5 million in the quarter primarily related to additional restructuring costs associated with the previously announced decision to partner or sell the small molecule drug discovery and development programs. Results for the second quarter of fiscal 2007 also included tax benefits of approximately $1.0 million related to the recognition of the prior fiscal year’s R&D tax credits as a result of the new tax legislation effective January 1, 2006. All per share amounts refer to Applera Corporation-Celera Group Common Stock.
